Skip to content

At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders. More »


November 13, 2014
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014

November 10, 2014
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission

More News »

Product Candidates

We have a pipeline of product candidates led by NUPLAZID™ (pimavanserin), which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »


Company Information

Investor's Kit Learn More: NUPLAZID™ (pimavanserin) Phase III Program for Parkinson's Disease Psychosis »
Investor Webcasts Investor Webcasts »
PDF Corporate Presentation »